Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
RESEARCH TOOLSreports
TLSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.50 - $10.42
Previous CloseN/A
Volume4.84K
Average Volume (3M)32.89K
Market Cap
$174.42M
Enterprise Value$134.33M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 27, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding30,493,137
10 Day Avg. Volume37,953
30 Day Avg. Volume32,892
Standard Deviation0.19
R-Squared0.02
Alpha-0.00797
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.49
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.45
Enterprise Value/Ebitda-2.56
Forecast
1Y Price Target
$10.60Price Target Upside83.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
TriSalus Life Sciences News
---
Bulls Say, Bears Say
Bulls Say
EarningsTriSalus Life Sciences announced preliminary Q4 revenue of ~$8.3M, beating the consensus expectation and improving significantly from previous quarters.
Product PerformanceTriNav had a tumor-to-normal ratio of 4.2 vs 2.7 for a traditional method, indicating its effectiveness in targeting tumors.
Revenue GrowthRevenue was up 42% year-over-year due to both activation of new accounts and deeper penetration within existing ones.
Bears Say
Leadership ChangesExecutive team shuffling sets the stage for a strong future.
Product DevelopmentNelitolimod in combination with immune checkpoint inhibitors did not show improvements in the treatment of liver metastases from uveal melanoma compared with historical data.
Stock DilutionThe upcoming reset for the company’s Convertible Preferred Stock could potentially double the shares, which might dilute current stock value.
---
Ownership Overview
44.52% Insiders
1.98% Mutual Funds
4.03% Other Institutional Investors
47.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.50 and its highest was $10.42 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $174.42M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Mar 27, 2025 which is in 32 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Nov 14, 2024. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.347 by $0.227.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.32.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 30,493,137 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.347. Following the earnings report the stock price went down -10.889%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
---
TriSalus Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.60 (83.71% Upside)
$10.60 (83.71% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $630.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.3%
Last 30 Days ▲ 32.0%
Last 30 Days ▲ 32.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.31%
12-Months-Change
Fundamentals
Return on Equity
271.41%
Trailing 12-Months
Asset Growth
-18.11%
Trailing 12-Months
Company Description
TriSalus Life Sciences
MedTech Acquisition Corp is a blank check company.
---
TLSI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
TriSalus Life Sciences shows strong revenue growth and operational improvements with significant product launches and market opportunities. However, the company faces challenges with cash flow management and dependency on future partnerships for further advancements.Read More>---
TLSI Stock 12 Month Forecast
Average Price Target
$10.60
▲(83.71% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Vertex Pharmaceuticals
―
Karyopharm Therapeutics
―
Moderna
―
Best Analysts Covering TLSI
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
-1.36%
reiterated a buy rating last month
Copying Justin Walsh's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -1.36% per trade.
---